The role of tumor necrosis factor in sepsis by Spooner, Christopher E. et al.
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 
Vol. 62, No. 1, January, pp. Sll-S17,1992 
The Role of Tumor Necrosis Factor in Sepsis’ 
CHRISTOPHER E. SPOONER,NORMAN P. MARKOWITZ, AND LOUISD.SARAVOLATZ 
Division of Infectious Diseases and Hospital Epiokmiology, Henry Ford Hospital, Detroit, Michigan 48202; and 
University of Michigan Medical School, Ann Arbor, Michigan 48109 
There is an increasing incidence of sepsis among hospital- 
ized patients. Also, high mortality associated with sepsis 
and septic shock persists despite appropriate antibiotic ther- 
apy. Recent investigations have demonstrated that bacterial 
antigens stimulate a cascade of cellular mediators or cyto- 
kine release. In sepsis and septic shock the response of these 
cytokines often exceeds natural downregulation and leads to 
multisystem organ failure and even death in an unaccept- 
ably high number of patients. Many investigative studies 
have shown that tumor necrosis factor (TNF) is the prime 
mediator of the inflammatory response seen in sepsis and 
septic shock. Sepsis management in the future will include 
immune modulating therapy directed against the deleteri- 
ous effects of cytokines, specifically TNF. This article re- 
views the current problem of sepsis and the evidence to sup- 
port the role of TNF in sepsis. Also, recent studies employ- 
ing monoclonal antibodies against TNF as well as 
considerations for future studies are discussed. o IWZ ACT- 
demic Press, Inc. 
INTRODUCTION 
The persistent high mortality and the increasing in- 
cidence of sepsis in hospitalized patients provide justi- 
fication for continued investigative efforts in under- 
standing and managing this most serious infection. Re- 
cent studies have demonstrated that a cascade of 
mediators are stimulated by bacterial antigens (l-7). 
Furthermore, measurement of these cellular factors or 
cytokines in animal models and human cases of sepsis 
supports the hypothesis that tumor necrosis factor 
(TNF) is a significant mediator of the clinical manifes- 
tations of sepsis. A major therapeutic goal that will be 
an integral part of managing sepsis in the future will 
be inhibiting the deleterious effects of cytokines, spe- 
cifically TNF, while maintaining their beneficial ef- 
fects. This article reviews the current problem of sepsis 
and the evidence to support the role of TNF as a me- 
diator of sepsis. In addition the results of published 
studies employing monoclonal antibodies against TNF 
1 Presented as part of a symposium entitled “Future Directions of 
Cytokine and Immunoglobulin Therapy,” January ll-12,1991, Tuc- 
son, AZ. 
are reviewed and considerations for future trials are 
discussed. 
SEPTICEMIAANDTHESEPSIS SYNDROME 
Septicemia is the 13th leading cause of death in the 
United States. Data from the National Hospital Dis- 
charge Survey of the Centers for Disease Control’s Na- 
tional Center for Health Statistics have demonstrated 
a 139% increase in the rate of septicemia from 1979 to 
1987 (8). The rate rose from 73.6/100,000 persons to 
175.9/100,000 persons. Although the rate increased 
among all age groups, the increase was greatest for 
persons over 65 years of age. In addition, septic shock 
is the most common cause of death among intensive 
care unit patients in the United States (5). Mortality 
rates from septic shock range from 40 to 90% (9-12). In 
a survey of septic patients seen at our institution in 
1989,35% died within the first 30 days and 50% within 
180 days. This is consistent with rates seen at other 
tertiary institutions which are seeing an increase in 
mortality compared to data from the early 1980s. 
Without uniformity of definitions, publications deal- 
ing with clinical trials or the epidemiology of sepsis, 
bacteremia, and septic shock may not be compared. 
The septic syndrome is an extremely important clinical 
entity since it serves as an early predictor of the more 
serious complications associated with septic shock and 
multiorgan failure. This is especially relevant when 
designing clinical trials which are aimed at blocking 
cellular mediators or bacterial toxins released early in 
the septic process. 
The definition of the septic syndrome is based on 
easily acquired clinical data (9, 13). The first criterion 
is clinical evidence of infection. There is not a require- 
ment for any positive culture. Furthermore, the pa- 
tient must exhibit the following signs: fever (>lOl”F) 
or hypothermia (<96”F), tachycardia (>90 beats/min), 
and tachypnea (>20 breaths/min while breathing 
spontaneously). The patients must also demonstrate at 
least one of the following manifestations of inadequate 
organ function or perfusion: altered mental status, 
hypoxemia (P,O, <70), elevated plasma lactate level, 
or oliguria (~30 ml for at least 1 hr). Using these cri- 
teria, Bone et al. reported on 191 patients of which 45% 
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developed bacteremia and 35% were in septic shock (9). 
Twenty-five percent developed the adult respiratory 
distress syndrome. The overall mortality for the sepsis 
syndrome was initially reported at 25%; however, re- 
cent data suggested that the mortality may be closer to 
50%. In an analysis of risk factors, Bone et al. noted a 
mortality of only 13% when shock was not present, but 
this rose to 43% when shock developed after admission 
(9). This definition of the septic syndrome allows one to 
look at the spectrum of this illness and provides a win- 
dow of opportunity for interventional clinical trials. 
Early therapy can halt the progression of a disease 
with a low mortality to one in which the effects of bac- 
terial toxins and cellular mediators have resulted in 
significant organ damage and an associated high mor- 
tality. 
PHYSIOLOGIC EFFECTS OF TNF 
Cytokines, produced by activated macrophages, 
serve to orchestrate a host-defense response against 
infection, injury, or inflammation. At times this re- 
sponse may lead to chronic inflammation, shock, mul- 
tisystem organ failure, and even death. One of the most 
important mediators of the inflammatory response is 
TNF. Human TNF alone has been shown to be able to 
conduct the complex orchestration of events leading to 
the inflammatory response. 
Although TNF was first isolated by Carswell et al. in 
1975 (14), the discovery was led by the knowledge that 
infection caused central necrosis of some tumors, espe- 
cially sarcomas, in both animals and humans. This ob- 
servation was made by William B. Coley, a New York 
City surgeon. In the late 19th century, Coley treated 
160 patients with killed bacteria, called “Coley’s tox- 
ins,” to treat sarcomas (15). The basis for the use of 
bacteria in treating tumors came from a number of 
isolated reports on erysipelas-induced tumor regres- 
sion (16). Coley’s toxins reproduced many of the symp- 
toms of bacterial infection such as fever and chills 
without causing actual infection. Interest in the poten- 
tial use of bacteria for the treatment of cancer was to 
remain alive in the laboratory. In 1943, Shear and his 
colleagues at the National Cancer Institute isolated 
and identified the active component of gram-negative 
bacteria, now called lipopolysaccharide (LPS) (17). 
These investigators went on to show that LPS could 
cause hemorrhagic necrosis of tumors, as well as an in- 
crease in animals’ resistance to new bacterial infections. 
In the 1950s Old and Benacerraf isolated and iden- 
tified the bacterial agent Bacillus Calmette-Guerin, or 
BCG. BCG was also shown to increase an animal’s re- 
sistance to subsequent bacterial infection and tumor 
growth. Carswell et al. went on to show that mice in- 
jected with both LPS and BCG produced large amounts 
of anti-tumor factors which they named “tumor necro- 
sis factor” (14). Old was then able to show that TNF 
was secreted by macrophages (18). 
In 1985, TNF was rediscovered by Cerami and co- 
workers. In searching for a substance responsible for 
anorexia and weight loss in chronic disease, these in- 
vestigators isolated a cytokine synthesized by macro- 
phages. This cytokine appeared responsible for pro- 
found wasting and lipemia in rabbits with trypanoso- 
miasis and, therefore, was named “cachectin” ( 19). 
Beutler and Cerami cloned the cDNA for mouse 
cachectin in 1986 (20) and proved it to be identical in 
homology to TNF -(Y cloned 1 year earlier by the re- 
searchers at Genentech Inc. (So. San Francisco, CA, 
(21). TNF-P was also cloned by Genentech and found to 
occur on the same chromosome (chromosome 6 in hu- 
mans) as TNF-cc. TNF-p has 30% homology to TNF-a 
and binds to the same receptor, and for the most part 
elicits the same response. TNF-P is produced primarily 
by T lymphocytes and therefore is called “lympho- 
toxin.” 
Once TNF was discovered, work was begun to de- 
velop a recombinant human tumor necrosis factor 
(rhTNF), for use as treatment for cancer. In 1987, re- 
searchers at the Institute of Cancer Research in Lon- 
don, England, treated 18 patients with advanced can- 
cer with intravenous rhTNF (22). The drug produced 
febrile reactions at all doses although these were pre- 
ventable by the administration of indomethacin and 
steroids. Doses at or above 9 x lo5 u were associated 
with hypotension, abnormal liver enzymes, leukope- 
nia, and mild renal impairment in a substantial num- 
ber of patients. These observations supported the bio- 
logic importance of TNF as an endogenous pyrogen and 
mediator of endotoxic shock. 
In 1988, researchers at Dana Farber Cancer Insti- 
tute, in Boston, administered rhTNF to 19 patients us- 
ing a 5-day continuous infusion. The maximum toler- 
ated dose was associated with undetectable TNF levels 
( ~0.2 u/ml). Certain tumor cells lines require TNF lev- 
els >l.O u/ml for the maximum desired in vitro cyto- 
toxicity (23). Attempts to utilize rhTNF as therapy for 
cancer have been unsuccessful due to the occurrence of 
systemic toxicity before therapeutic levels can be 
reached. Recently, researchers have developed a way 
to expose only the patient’s tumor to TNF, avoiding 
systemic toxicity, through gene transfer therapy. This 
type of therapy involves introducing the gene for TNF 
into the patient’s tumor-infiltrating lymphocytes. 
which selectively traffics to the tumor without expos- 
ing the whole system. 
In June of 1988, researchers at the Brigham and 
Women’s Hospital measured plasma concentrations of 
TNF-a, interleukin-1-P (IL-l-p) and interferon (IFN) 
together with physiologic and hormonal responses, in 
21 healthy men after administration of Escherichia 
coli endotoxin (4 mg/kg) and during a control period of 
saline administration (24). Eight subjects received ibu- 
profen before receiving endotoxin or saline. TNF was 
the only cytokine that became elevated in the blood- 
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stream of these patients. Also, from 60 to 90 min after 
endotoxin administration, the elevation of TNF was 
associated with all other patient responses. Flu-like 
symptoms of chills, headaches, myalgias, and nausea 
were most severe when concentrations of circulating 
TNF were maximal. Fever and stress-related hormone 
elaboration persisted for 2 hr or more after TNF was no 
longer detected in the circulation. 
INTERACTIONS, SYNERGY WITH OTHER BRMs 
(LPS, IL-l, IFN) 
TNF, primarily TNF-a, plays a central role in the 
inflammatory response. TNF is one of many cytokines 
which are involved in a variety of physiologic re- 
sponses. Cytokines play a major role in the pathophys- 
iology of many diseases including septic shock. Some 
have already been found to have therapeutic potential. 
Strategies for new therapies involve the modification 
of cytokine levels or receptors through the use of im- 
mune modulating agents or gene therapy. 
New information and new cytokines are continually 
being reported. The network of cytokines is as diverse 
as it is complex. Numerous reports now support the 
hypothesis that TNF synthesis is under strict regula- 
tion by other cytokines and immune modulators. It is 
now known that interferon-y (IFN-~1, when released 
by activated T lymphocytes, is a potent macrophage 
stimulus that can enhance a number of macrophage 
activation parameters. An increase in macrophage 
TNF has been shown to be mediated by IFN-y. Inter- 
estingly, IFN--y is unable to stimulate release of mac- 
rophage-derived TNF by itself, but is capable of aug- 
menting LPS-induced TNF release (25). 
In 1988, Kunkel et al. showed that LPS-stimulated 
macrophages could induce a concomitant increase in 
monokine synthesis, and cycle-oxygenase-derived 
prostaglandin Ez (PGEz) may act as a control on TNF 
production (26). Furthermore, in LPS-induced macro- 
phages, TNF is regulated not only by PGE, but also by 
an additional cycle-oxygenase-derived lipid metabolite 
prostacyclin (PGIz), which can also suppress TNF pro- 
duction. This regulatory effect that PGE, and PGI, 
have on TNF production may play an important role in 
altering the inflammatory response. However, the reg- 
ulation of the inflammatory responses may only be lo- 
cal, since systemic PGEz treatment has no in uiuo ef- 
fects on preformed TNF (27). 
In 1989, Essner et al. demonstrated the negative ef- 
fects that IL-4 had upon TNF (28). It has also been 
shown that transforming growth factor 8 (TGF-8) sup- 
presses TNF production (29). As little as 10 rig/ml of 
TGF-8 was shown to reduce LPS-dependent TNF pro- 
duction by greater than 50%. TGF-8 was also shown to 
inhibit the augmenting effect of IFN--y on TNF produc- 
tion. Interestingly, other mediators do not appear to be 
affected by TGF-8. 
In January of 1990, Takayama et al. found massively 
elevated mono&e TNF-a and PGEz production to be 
occurring simultaneously in trauma patients with sep- 
sis (30). The high concentration of PGEz did not appear 
to downregulate the elevated total monocyte TNF-a: 
levels in these patients. Patients in whom sepsis did 
not develop had total TNF-(w concentrations well below 
the levels of most patients with septic complications. 
Patients with extremely high total TNF-a levels dur- 
ing Days l-3 after injury were reported to have a 100% 
mortality. The trauma patients with sepsis showed in- 
creased total (cell-associated plus secreted) monocyte 
TNF-(Y levels occurring concomitantly with massive el- 
evation in their monocyte PGEz levels. The peak ele- 
vation in total monocyte TNF-a levels of patients cor- 
related with septic episodes as early as 3 days before 
overt sepsis. These data suggest that trauma-induced 
production of mediators may be counteracting the 
downregulatory effect of PGEz on TNF-IX mRNA ex- 
pression, as well as inducing TNF-cx production. 
The ability of cytokines to influence the production of 
other cytokines emphasizes the complexity of interac- 
tions that may occur with protein mediator synthesis 
in the inflammatory or other physiologic responses. 
The host shows considerable efforts to protect itself 
from excessive TNF levels. Once the immune system is 
triggered there is a burst of TNF synthesis followed by 
decreased production. It is suspected that TNF produc- 
tion may be exaggerated during sepsis or septic shock 
to too great a degree or too early for regulatory factors 
to prevent its serious systemic toxicity-potentially 
leading to end-organ failure or death. 
TNF INFUSION STUDIES 
In 1986, Tracey and Beutler showed that shock and 
tissue injury could be elicited by injecting recombinant 
human cachectin into rats (31). When administered in 
quantities similar to those produced endogenously in 
response to endotoxin, rhTNF was shown to produce 
hypotension, metabolic acidosis, hemoconcentration, 
and death within minutes to hours. At necropsy, diffuse 
pulmonary hemorrhage and inflammation, ischemic 
and hemorrhagic lesions of the gastrointestinal tract, 
and acute renal tubular necrosis were found. It ap- 
peared that rhTNF alone was capable of inducing the 
many deleterious effects of endotoxin. This was sup- 
ported by data published in 1987 by Bauss et al. from 
Heidelberg, Germany, showing that TNF alone could 
elicit pathophysiologic effects in mice which were in- 
distinguishable from those produced by endotoxin of 
LPS (32). 
Tracey et al. again showed that lethal shock and 
stress hormonal responses could be demonstrated 
when TNF-a was administered by intra-arterial infu- 
sion in two groups of beagle dogs at lethal (100 mg/kg) 
and sublethal (10 mg/kg) doses. The infusions produced 
serum cachectin levels (1 to 50 nmol/liter) similar to 
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those seen after experimental endotoxemia (33). The 
lethal response to cachectin/TNF was characterized by 
progressive hypotension, shock, and death within 3 hr. 
Histopathologic findings included acute inflammation 
of pulmonary interstitium with intravascular throm- 
bosis, hemorrhagic necrosis, adrenal medullary necro- 
sis, and acute renal tubular necrosis. TNF infusion in- 
duced a significant increase of plasma catecholamines, 
cortisol, and glucagon in a dose-response manner (34). 
This study showed that the infusion of rhTNF, at doses 
that could be produced in response to bacteremia, stim- 
ulates progressive hemodynamic collapse, shock, and 
death. These observations suggested an important role 
for cachectin/TNF in the mobilization of host energy 
stores and the development of shock after infection. 
TNF IN CLINICAL SEPSIS 
In February 1987, Waage and Espevik reported an 
association between TNF in serum and fatal outcome 
in patients with meningococcal disease. Serum sam- 
ples were taken on admission from 79 patients with 
meningococcal meningitis, septicemia, or both, and 
were examined in a highly sensitive bioassay for TNF. 
TNF was detected in samples from 10 of 11 patients 
who died but from only 8 of 68 survivors. All 5 patients 
with serum TNF levels over 440 u/ml died (35). 
In August 1988, Girardin et al. investigated cytokine 
levels in the serum of children with severe infectious 
purpura in order to analyze the relation between se- 
rum cytokine levels and clinical and biologic risk fac- 
tors in those children. The data published provided ev- 
idence that serum levels of TNF-CY, IL-l, and IFN-y 
correlated with the severity of meningococcemia in 
children (36). 
Many investigators began to look at plasma TNF-a 
levels and mortality in critically ill septic patients. Re- 
searchers from the Department of General Surgery, 
University of Limburg, The Netherlands, measured 
plasma TNF levels in 43 septic patients suffering from 
a broad range of diseases. The data obtained demon- 
strated that sepsis was accompanied by detectable cir- 
culating TNF in 25% of the cases, and for those pa- 
tients the mortality was twice that for comparable 
TNF-negative patients (37). Damas et al., from the 
University of Leige, Belgium, Studied serum TNF-a 
levels and IL-l levels in patients developing sepsis in 
the intensive care unit. They also reported a correla- 
tion between TNF-o levels and sepsis severity as well 
as mortality. In contrast, IL-l-p levels did not correlate 
with the severity of sepsis or mortality (38). Marks et 
al. at the University of California, San Francisco, as- 
sayed serum samples from 86 patients who were en- 
rolled in a prospective randomized trial of the effects of 
methylprednisolone in sepitc shock. TNF was detect- 
able in 27 of 74 patients with septic shock and only 1 of 
12 patients with shock due to other causes. TNF was 
detected with equal frequency in patients with shock 
from gram-negative or from gram-positive sepsis. Fur- 
thermore, the patients with detectable TNF had a 
higher incidence and severity of the adult respiratory 
distress syndrome and a higher mortality rate than did 
patients without detectable TNF (391. 
TNF MONOCLONAL ANTIBODY STUDIES 
With the availability of monoclonal antibody (MAb) 
hybridoma technology, the feasibility of blocking the 
deleterious effects of TNF has been realized. 
Several animals have been studied to evaluate the 
protective role of passive immunization against TNF 
from the effects of endotoxin. Beutler et al. immunized 
mice with rabbit antibody against murine TNF and 
challenged them with lethal amounts of LPS (40). 
There was a significant reduction of mortality at 7 days 
in mice passively immunized compared to control ani- 
mals. The protection was dose-dependent and most ef- 
fective when administered prior to the injection of en- 
dotoxin. Of note, the anti-TNF did not abrogate the 
pyrogenic effects of LPS. 
A recent study by Opal et al. demonstrated the effi- 
cacy of antibody against TNF in a neutropenic rat 
model in protecting animals from lethal infection with 
Pseudomonas aeruginosa (411. This model was estab- 
lished to mimic the pathophysiology of bacterial infec- 
tion as it occurs in patients receiving cancer chemo- 
therapy. The role of MAb directed against TNF was 
assessed alone and in combination with antimicrobial 
agents. TNF MAb was given at Time 0 and 120 hr 
while the P. aeruginosa challenge was given at 0, 48, 
and 96 hr. Intravenous administration of TNF MAb 
protected 53.3% (8/15) of animals in contrast to no sur- 
vivors in untreated control animals (P < 0.005). When 
animals were given ciprofloxacin alone, 67% survived, 
while the combination treatment group afforded com- 
plete protection CP < 0.05). The study demonstrated 
not only that there was a reduction in mortality with 
TNF MAb, but also that there was a delay in lethality 
for up to 72 hr in septic animals. Furthermore, the 
circulating levels of TNF were significantly lower in 
the animals receiving anti-TNF than in control ani- 
mals. This study provides objective in uivo data to sup- 
port the therapeutic additive protective benefit of com- 
bination antimicrobial therapy and anti-TNF therapy. 
In an additional set of experiments by Silva et al., a 
hamster MAb directed against TNF-a was developed 
and administered to mice as prophylaxis and therapy 
against E. coli (42). There was significant improve- 
ment in survival at 3 days if given before and up to 1.5 
hr after bacterial challenge. If given at 2.5 hr after 
bacterial challenge, TNF MAb improved survival from 
12 to 25%; however, this difference was not significant. 
The protective benefit of TNF MAb was present, but 
less for infection caused by P. aeruginosa than that by 
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E. coli. Furthermore, no significant difference could be 
seen in mice treated prophylactically with TNF MAb 
who were neutropenic and infused with Klebsiella 
pneumoniae when compared to control animals. These 
same investigators measured TNF-d levels prior to and 
at various intervals for up to 5 hr after bacterial chal- 
lenge. A very rapid rise in serum TNF-o levels to 153- 
232 rig/ml occurs between 50 and 90 min after bacterial 
infusion and then drops to levels of 10-12 rig/ml within 
5 hr, suggesting a very rapid clearance. Peak levels of 
TNF-a vary with the amount of LPS injected as well as 
the animal species studied. An additional observation 
by Silva et al. was that the entire physiologic responses 
of mice treated with anti-TNF-d were identical to those 
of the control group for up to 6-8 hr after bacterial 
challenge. These observations are consistent with evi- 
dence suggesting that the pathophysiologic effects of 
LPS are due to mediators in addition to TNF-IX, such as 
interleukins and interferons. Another explanation for 
these observations is that the physiologic responses are 
centrally mediated, where the transfer of passive anti- 
body would not be expected to be effective since central 
nervous system levels would be difficult to achieve. The 
major conclusion drawn from this study is that anti- 
TNF treatment of mice prevented events leading to 
death. Furthermore, this benefit was not due to en- 
hanced bacterial clearance. 
Tracey et al. have studied the role of passive immu- 
nization against TNF-c~ in baboons (43). These studies 
involved evaluating only anti-TNF in prophylactic ex- 
periments. Although a limited number of baboons were 
evaluated, the authors demonstrated that when anti- 
TNF was given to three baboons 1 hr before challenge 
with a lethal inoculum of E. coli, animals were pro- 
tected against shock but not multiorgan failure lead- 
ing to death. However, when anti-TNF was adminis- 
tered 2 hr before bacterial challenge, all animals sur- 
vived and were protected from shock as well as 
multiorgan failure. 
In a subsequent publication using the original model 
of Tracey et al., Fong et al. reported on the effect of 
anti-TNF on other cytokines (44). These authors re- 
ported that IL-l-l3 appears slightly later than TNF, 
being detectable by 2 hr and peaking 3 hr after bacte- 
rial infusion. IL-6 appeared even later, at 3 hr, and 
continued to rise throughout 8 hr of the experimental 
observations. Experimental models have suggested 
that TNF induces the biosynthesis of IL-l and IL-6 as 
secondary mediators. Levels of IL-l-l3 and IL-6 were 
significantly reduced when anti-TNF was given at both 
1 and 2 hr before bacterial challenge. These observa- 
tions add further weight to the importance of TNF as a 
major mediator of sepsis. 
Hinshaw et al. further evaluated the role of anti- 
TNF in a model of lethal E. coli-induced shock (45). In 
these experiments the investigators infused the lethal 
dose of E. coli over 2 hr and the anti-TNF was initiated 
30 min after the onset of the E. coli infusion. All ani- 
mals treated with anti-TNF survived the full 7 days of 
the experiment until they were sacrificed at Day 7. 
Furthermore, multiorgan failure was prevented as 
well as death with anti-TNF. When animals were not 
treated with anti-TNF, the mean survival time was 19 
hr after injection of E. coli. 
To date there has been only one study published 
evaluating anti-TNF in humans. In a Letter to the Ed- 
itor in Luncet, Exley et al. reported on a Phase 1 study 
of 14 patients with severe septic shock who were ad- 
ministered CB00006, which is a murine IgG K MAb 
directed against TNF-d (46). Doses were 0.4, 2.0, and 
10 mg/kg. In this study CB00006 was found to be safe 
and without acute side effects. Human anti-mouse an- 
tibodies (HAMA) were demonstrated and could be im- 
portant if repeated administration is required. 
CONSIDERATIONS FOR CLINICAL TRIALS 
WITH ANTI-TNF 
Future trials with TNF MAb will be a fertile area for 
investigative efforts in the immunotherapy of sepsis. 
However, these trials will require careful consider- 
ation in their design in order to ensure that the critical 
issues dealing with efficacy are satisfactorily ad- 
dressed. 
Antimicrobial selection should be standardized in an 
efficacy trial to determine the real benefit of immuno- 
therapy with agents such as TNF MAb and to exclude 
the confounding effect that could be seen if agents of 
varying in vitro antimicrobial activity are selected. Al- 
though this standardization seems desirable, the in 
uiuo superiority of individual antimicrobial agents or 
specific combinations is seldom shown in a statistically 
significant fashion in comparative efficacy trials. Fur- 
thermore, resistance patterns, institutional cost con- 
siderations, and individual clinician’s subjective pref- 
erences make standardization of antimicrobial therapy 
extremely cumbersome. The advantage of not stan- 
dardizing antimicrobial therapy when evaluating im- 
munotherapeutic modalities is that the study will re- 
flect how these agents might work in the “real world” 
by current practice standards. 
The definition of sepsis represents a most difficult 
and important consideration for clinical trials. The def- 
inition proposed by Bone et al. is accepted by many 
clinicians, but does have some limitations (9). Patients 
often do not fulfill all the criteria at a single point in 
time. Therefore, it is important for the clinician to rec- 
ognize the “evolving septic syndrome.” The patient 
must manifest the signs of the septic syndrome over a 
12-hr period. Even using these criteria, only 40 to 45% 
of patients will have associated bacteremias. Further- 
more, patients, especially the elderly, will fail to man- 
ifest signs of sepsis in the face of positive blood cul- 
tures. The major advantage of recognizing the evolving 
septic syndrome is the ability to recognize an earlier 
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stage of sepsis in a patient that will progress to septic 
shock, multiorgan failure, and death. Thus, in spite of 
its limitations in sensitivity and specificity, Bone’s def- 
inition probably offers the best current definition of an 
early predictor of the more serious sequelae of sepsis. 
The ability to recognize the septic patient is essential 
in defining the optimal timing for immunotherapeutic 
interventions. The general philosophy of “the earlier 
the better” is clearly supported by the animal studies 
discussed above. Trials that adhere strictly to a very 
narrow time period after signs of sepsis appear are 
most likely to demonstrate a benefit from an interven- 
tion directed against the release of TNF. However, this 
will leave many questions unanswered. Clinical situa- 
tions in which patients present after 12 hr from their 
first signs of sepsis will occur. In addition, some pa- 
tients will present with an incomplete septic syndrome 
or a chronic septic appearance. These patients who do 
not meet the criteria for the septic syndrome may still 
benefit from anti-TNF therapy but will not be evalu- 










The effect of HAMA will be of importance for murine 
anti-TNF, especially if the patient has previously re- 
ceived monoclonal preparations such as OKT-3 or the 
murine monoclonal anti-lipid A product. This consid- 
eration is important for clinical trials but is more im- 
portant for future clinical practice where physicians 
will be using a variety of MAbs in clinical situations. 
A final consideration for a clinical trial and the clin- 
ical practice of immunotherapy will be the use of com- 
bination agents. The potential for combination mono- 
clonal therapy with anti-lipid A and anti-TNF has 
merit by inhibiting two distinct and important media- 
tors of sepsis. MAbs may also be considered to block 
other cytokines such as IL-l and IL-6 and may become 
part of an MAb “cocktail” used in the therapy of sepsis. 
Clinical trials evaluating the role of TNF MAb will 
be performed in the near future. These studies will 
capitalize on biotechnology and our improved under- 
standing of the mediators of sepsis. Antibiotics have a 
limited role in the management of the patient with 
septic shock beyond the lysis of the causative bacteria. 
Therapy directed against circulating toxins or media- 
tors such as TNF has fueled our interest in using im- 
munotherapy to neutralize the deleterious effects of the 
mediators of septic shock. It is hoped that TNF MAb 
will provide a major advance to our therapeutic ap- 
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